News

Kesimpta Shows Promising Results for MS Patients Switching Therapies

Kesimpta Shows Promising Results for MS Patients Switching Therapies

Significant Advances with Kesimpta in Managing Relapsing MS

Recent studies have showcased the substantial potential of Kesimpta (ofatumumab) in providing relief for individuals afflicted with relapsing multiple sclerosis (RMS). The data was derived from two pivotal studies presented at a significant European conference focused on multiple sclerosis research and treatment.

Effective Shift from Oral Disease Modifying Therapies

The ARTIOS Phase IIIb study, an open-label, single-arm, prospective investigation, revealed a remarkable reduction in disease activity among patients transitioning to Kesimpta after experiencing breakthrough disease on previous oral disease-modifying therapies (DMTs) like fingolimod or fumarate-based treatments. Patients exhibited a notably low annualized relapse rate (ARR) of 0.06 over a period of 96 weeks, a clear indicator of improved disease management.

One of the most striking findings from the study indicated that more than 90% of the participants achieved no evidence of disease activity (NEDA-3). These results signify a noteworthy advancement for MS patients suffering from inadequate responses to their previous therapies, illustrating Kesimpta's effectiveness in stabilizing their condition.

Long-Term Efficacy of Kesimpta

In a complementary study known as ALITHIOS, which included treatment-naïve patients diagnosed within the last three years, over 90% were reported to be progression-free after seven years of receiving Kesimpta as their first-line treatment. This emphasizes the importance of initiating treatment early, as long-term efficacy was supported by consistently low ARR and a steady safety profile across different patient demographics.

Continued Safety Assurance

Lead investigator, Dr. Riley Bove, from a renowned university in California, noted the compelling evidence that supports Kesimpta's safety and efficacy. The findings indicate robust disease control sustained over a two-year period for patients who previously struggled with their oral DMT regimens. The absence of new safety concerns after switching to Kesimpta further bolsters the therapy's appeal in managing RMS effectively.

Kesimpta Details

Kesimpta functions as a targeted B-cell therapy, administered once a month through a convenient subcutaneous injection. This innovative treatment allows for self-administration by patients, ensuring flexibility and ease of use. During the initiation phase, doses are strategically timed across the first month, with initial injections monitored under healthcare supervision to maximize safety and efficacy.

Understanding Multiple Sclerosis

Multiple sclerosis is a chronic condition marked by inflammation and damage to the central nervous system, affecting millions globally. MS exacerbates neurological function and can manifest in various forms, such as relapsing-remitting and secondary progressive types. This complexity necessitates effective therapeutic strategies, making advances like Kesimpta significant in the treatment landscape.

Novartis's Commitment to Neuroscience

As an industry leader in tackling neurological conditions for over eight decades, Novartis continuously innovates to provide transformative medications. Their commitment to developing solutions for multiple sclerosis and other neurological disorders underscores their dedication to enhancing patient care worldwide.

Frequently Asked Questions

What is Kesimpta used for?

Kesimpta is prescribed for adults with relapsing forms of multiple sclerosis, including active secondary progressive disease.

How does Kesimpta work?

Kesimpta is an anti-CD20 monoclonal antibody that targets specific B-cells, which play a crucial role in the immune response related to MS.

What are the common side effects of Kesimpta?

Common side effects may include upper respiratory infections, headaches, and potential injection-related reactions.

How often is Kesimpta administered?

Kesimpta is administered via subcutaneous injection once a month after initial doses are given during the first three weeks.

What should patients discuss with their healthcare provider before starting Kesimpta?

Patients should inform their healthcare providers about their medical history, especially concerning infections and any medications affecting their immune system.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading